What is Rapid Pathogen Screening?
Rapid Pathogen Screening specializes in the development, manufacturing, and marketing of cost-effective point-of-care tests designed to address systemic infectious diseases and promote antibiotic stewardship. Its flagship product, the FebriDx test, serves as a pivotal tool in clinical settings, utilizing a finger-stick blood sample to differentiate between bacterial and viral causes of fever in acute respiratory infections. With a 97% negative predictive value and a 15-minute turnaround time, the technology provides clinicians with actionable data to optimize patient triage and reduce the unnecessary prescription of antibiotics. This focus on rapid, in-office diagnostics places the company at the intersection of medical innovation and public health efficiency.
How much funding has Rapid Pathogen Screening raised?
Rapid Pathogen Screening has raised a total of $34.6M across 3 funding rounds:
Unspecified
$6.3M
Debt
$28M
Debt
$350K
Unspecified (2013): $6.3M with participation from Mallitz Investment Group
Debt (2014): $28M led by OrbiMed Advisors, LLC
Debt (2020): $350K supported by PPP
Key Investors in Rapid Pathogen Screening
OrbiMed Advisors, LLC
OrbiMed Advisors LLC is a specialized healthcare investment firm with deep expertise across biopharmaceuticals, medical devices, and diagnostics. The firm manages capital for companies at various stages of development, providing both financial backing and operational insights to drive innovation in life sciences.
Mallitz Investment Group
The Mallitz Investment Group is a family office platform that employs a debt-oriented strategy to invest in private, proprietary transactions. The firm utilizes institutional-level discipline in screening and due diligence to achieve risk-mitigated returns within the healthcare and private equity sectors.
PPP
Public-Private Partnership
What's next for Rapid Pathogen Screening?
With the recent capital infusion, Rapid Pathogen Screening is poised to scale its operational capacity and deepen its penetration into clinical markets. The strategic focus will likely center on expanding the adoption of the FebriDx platform, which is essential for modernizing infectious disease management. As the company moves forward, it will likely leverage its diagnostic capabilities to address broader challenges in antibiotic stewardship, potentially exploring new diagnostic markers or expanding its footprint in international healthcare systems. The firm's ability to deliver high-accuracy results in a rapid timeframe provides a competitive advantage that will be critical as it seeks to establish its technology as a standard of care in primary and urgent care settings.
See full Rapid Pathogen Screening company page
